Porton Pharma Solutions

Porton Pharma Solutions, also known as Porton, is a pharmaceutical contract development and manufacturing organization (CDMO) founded in 2005 and headquartered in Chongqing, China. It provides customized research and development and GMP manufacturing services to pharmaceutical and biotechnology companies and research institutions. The company describes its work as spanning the drug lifecycle, from preclinical development through commercialization, and positions itself as a customer-centric provider of global CDMO solutions. Its service portfolio covers drug substances and drug products in several modalities. These include small molecules; TIDES, covering peptide and oligonucleotide drug services; biologics and conjugates, including ADCs and other conjugate formats; and advanced therapy medicinal products. The TIDES platform describes services ranging from early research and process development to manufacturing, formulation development, analytical method development and validation, and regulatory support. Porton’s general service offering also includes R&D and GMP manufacturing. The company’s website identifies facilities and offices in China, including Chongqing and Shanghai, as well as locations in Switzerland, Belgium, and the United States. It describes its solutions as global and its customer base as international. Porton states that its mission is to enable earlier access to good medicines and that its vision is to become an open, innovative, and reliable pharmaceutical services platform. Its listed corporate values include putting customers first, teamwork, efficient execution, embracing change, and pursuing excellence. The website describes Porton as having become a public company during its 2010–2016 development phase; the supplied material does not specify its listing date, exchange, or ticker.

Porton Pharma Solutions was founded in 2005. Its corporate history page identifies its earliest phase, from 2005 to 2009, as the period in which it started as a contract manufacturing organization (CMO). The company lists the founding of Porton in 2005 and the commissioning of the Changshou API plant and Chongqing R&D Center in 2006. The supplied page also names the establishment of Porton US and European offices in 2008, though the available excerpt ends before providing further detail. Porton describes 2010–2016 as the period in which it was listed as a public company. It characterizes 2017–2022 as a transformation into an end-to-end CDMO. For 2023 onward, the company describes an expansion to all modalities and an ambition to become a global leading CDMO. Its current stated service scope includes small molecules, TIDES, biologics and conjugates, and advanced therapy medicinal products, with R&D and GMP manufacturing services. The company presents its operating model as customer-focused and global, serving pharmaceutical and biotechnology companies and research institutions. Its stated mission is to enable earlier access to good medicines. The provided evidence does not identify the company's founder, precise listing details, or named executives, and does not establish additional dated corporate milestones beyond those summarized here.

• 2023

  Expansion across modalities

• 2017

  End-to-end CDMO transformation phase began

• 2008

  U.S. and European offices established

• 2006

  Changshou API plant and Chongqing R&D Center commissioned

• 2005

  Porton founded

• Became a public company

A customer-centric, innovative and reliable global CDMO offering customized development and GMP manufacturing services across multiple drug modalities and stages of the drug lifecycle.

• Small Molecules CDMO Services

  CDMO services for small-molecule drug development and manufacturing.

• TIDES CDMO Services

  A peptide and oligonucleotide drug service platform covering research, process development, manufacturing, formulation, analytical work, and regulatory support.

• Biologics and Conjugates CDMO Services

  CDMO services for biologics and conjugates, including ADCs and other conjugate formats named by the company.

• Advanced Therapy Medicinal Products CRO & CDMO Services

  CRO and CDMO services for advanced therapy medicinal products.

• 2015

  Source

Read more

• 2020-07-09

  Boteng announces 2020 half-year earnings forecast[6]博腾股份发布2020年半年度业绩预告finance.sina.com.cn

  Reported: 2020-07-13

  Boteng announced a forecast for the first half of 2020, projecting net profit of 124–137 million yuan, up 90%–110% year over year, and revenue of 906–937 million yuan, up 45%–50%.

• 2020-03-11

  XtalPi and Porton sign strategic collaboration[7]晶泰科技与博腾股份签署战略合作prnewswire.com

  Reported: 2020-03-11

  XtalPi and Porton signed a strategic collaboration to combine XtalPi's computational tools with Porton's experimental expertise for pharmaceutical research and development. Their U.S. subsidiary J-STAR also signed a sub-agreement to launch prediction-guided crystallization and solid-state research services for U.S. customers.

• 2019-12

  Porton Pharma Solutions receives 2019 China Benevolent Enterprise award[8]博腾股份荣获“2019年度中国仁心企业”称号finance.sina.com.cn

  Reported: 2019-12-13

  Porton Pharma Solutions received the “2019 China Benevolent Enterprise” award at the 2019 CSR Pioneer Forum and corporate social responsibility awards ceremony in Beijing. The source describes the ceremony as having taken place recently but does not give its exact date.

1. 1End-to-end CDMO | Porton Pharma Solutionsportonpharma.com
2. 2Discover Porton Pharma: Our Mission, Values, and Expertiseportonpharma.com
3. 3Corporate Governance Strategies for Sustainable Growth | Porton Pharmaportonpharma.com
4. 4Comprehensive Tides CDMO Services for Drug Development | Porton Pharmaportonpharma.com
5. 5委托运输废水被倾倒入河，子公司犯污染环境罪vip.stock.finance.sina.com.cn
6. 6博腾股份发布2020年半年度业绩预告finance.sina.com.cn
7. 7晶泰科技与博腾股份签署战略合作prnewswire.com
8. 8博腾股份荣获“2019年度中国仁心企业”称号finance.sina.com.cn